RBC Capital analyst Luca Issi reiterated an Outperform rating and $150.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Cowen on Intellia Therapeutics (NTLA): 'We continue to view NTLA as a leader in the gene editing space'August 4, 2022 11:06 AM Increasing unusual put option volume: SFM MQ QSR RVLV RCII ALL FTNT TNDM NTLAAugust 4, 2022 10:08 AM Intellia Therapeutics (NTLA) Misses Q2 EPS by 5cAugust 4, 2022 7:55 AM Form 8-K Intellia Therapeutics, For: Aug 04August 4, 2022 7:47 AM Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company ProgressAugust 4, 2022 7:30 AM Intellia Therapeutics (NTLA) PT Raised to $68 at WedbushAugust 3, 2022 2:42 PM